To compare the angiotensin-converting enzyme (ACE) inhibitor perindopril, alone or in combination with the diuretic indapamide, to placebo in the secondary prevention of stroke and other major cardiovascular events.
- Antihypertensives Drug
Intervention Desc: This category includes all BP lowering drugs in stroke prevention trials
- Perindopril (Aceon)Drug
Intervention Desc: Antihypertensive; angiotensin converting enzyme (ACE) inhibitor
Randomized, double-blind, placebo-controlled, international, trial of 6105 patients at 172 centers.
Patients were randomly assigned to treatment with the ACE inhibitor perindopril 4 mg or placebo, plus the diuretic indapamide (for individuals in whom it was not considered to be definitely indicated or contraindicated) or placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Total number of strokes defined by WHO criteria.|
|Secondary||Fatal and disabling strokes, total number of cardiovascular events and deaths, cognitive function, disability, and dependency. Mean follow-up is 3 years.|